MCET News MultiCell Technologies Discusses Recent Cancer Treatment Breakthrough and Growing Intellectual Property Portfolio with CEOcast.com Investor Information Service
SAN DIEGO--(BUSINESS WIRE)--MultiCell Technologies, Inc. (OTCBB:MCET),
developing first-in-class drugs based on advanced immune system
modulation and other proprietary technologies, announced the
availability of a new interview in which Chief Executive Officer Dr.
Stephen Chang discusses recent key achievements and breakthroughs with
online investor information service CEOcast.com.
In the online interview, Dr. Chang highlighted recent research data that
shows how MultiCell’s unique technology
platforms, designed to treat disease by modulation of the human immune
system, may have valuable application as a treatment for deadly diseases
such as cervical cancer and other cancers that are caused by viruses.
“MultiCell has shown remarkable progress over
the past few months,” said Dr. Chang. “I
hope this interview gives investors a better understanding of our
accomplishments and ongoing potential as we develop first-in-class drugs
targeting diseases related to immune system disorders.”
Dr. Chang also discussed the Company’s growing
intellectual property portfolio that recently passed the 70 issued or
pending patent threshold. MultiCell is leveraging its breakthrough
technology platforms to develop a new generation of therapeutic
candidates which stimulate or suppress the immune system to treat such
conditions as multiple sclerosis, type-1 diabetes, virally caused
cancers, and infectious disease.
The interview can be accessed at the MultiCell Technologies company
profile on http://www.ceocast.com.
About MultiCell Technologies, Inc.
MultiCell Technologies, Inc. is an integrated biopharmaceutical company
committed to the development of breakthrough therapeutics based on a
portfolio of therapeutic candidates and patented drug development
technology. MultiCell’s drug development
program is focused on modulation of the immune system. MultiCell’s
therapeutic pipeline includes drug candidates some of which are in
various advanced stages of human clinical trials. These therapies
include:
MCT-125 for the treatment of chronic fatigue in MS patients. MCT-125
completed a Phase II clinical trial and demonstrated significant
efficacy in reducing chronic fatigue in MS patients. There is no drug
specifically approved for the treatment of chronic fatigue in MS
patients anywhere in the world.
MCT-175 for the treatment of relapsing-remitting MS. MCT-175, in
preclinical development for the treatment of relapsing-remitting MS,
targets disease specific autoaggressive T-cells that destroy the
myelin sheath of nerve cells. MCT-175 successfully ameliorated the
disease in animal models.
MCT-275 for the treatment of type-1 diabetes. MCT-275, in preclinical
development, targets disease-specific autoaggressive T-cells that
destroy insulin producing cells in the pancreas. MCT-275 completely
reversed the type-1 diabetic phenotype and prolonged life in animal
models.
MCT-465 in an adjuvant therapy for the treatment of virus infection
and cancer. MCT-465 in preclinical studies successfully reduced
pulmonary influenza virus levels 1,000-fold in animal models, and has
demonstrated effectiveness in reducing virus levels of HIV and HCV in
animal models. MCT-465 in preclinical studies successfully eliminated
certain types of tumors in animal models.
The Company also holds unique cell-based technology for use in drug
discovery screening applications, and is a leading producer of the cell
lines needed by the biotechnology industry to develop new drugs and
therapeutics.
Any statements in this press release about MultiCell's expectations,
beliefs, plans, objectives, assumptions or future events or performance
are not historical facts and are forward-looking statements for purposes
of the Private Securities Litigation Reform Act of 1995 (the "Act").
These statements are often, but not always, made through the use of
words or phrases such as "believe," "will," "expect," "anticipate,"
"estimate," "intend," "plan," "forecast," "could" and "would." Examples
of such forward-looking statements include statements regarding
developing products that address unmet medical needs. MultiCell bases
these forward-looking statements on current expectations about future
events. They involve known and unknown risks, uncertainties and
assumptions that may cause actual results, levels of activity,
performance or achievements to differ materially from those expressed or
implied by any forward-looking statement. Some of the risks,
uncertainties and assumptions that could cause actual results to differ
materially from estimates or projections in the forward-looking
statement include, but are not limited to, the risk that we might not
achieve our anticipated clinical development milestones, receive
regulatory approval, or successfully commercialize our lead drug
candidates as expected, the market for our products will not grow as
expected, and the risk that our products will not achieve expectations.
For additional information about risks and uncertainties MultiCell
faces, see documents MultiCell files with the SEC, including MultiCell's
report on Form 10-KSB for the fiscal year ended November 30, 2005, and
all our quarterly and other periodic SEC filings. MultiCell claims the
protection of the safe harbor for forward-looking statements under the
Act and each assume no obligation and expressly disclaim any duty to
update any forward-looking statement to reflect events or circumstances
after the date of this news release or to reflect the occurrence of
subsequent events.
